References
- Cancer Statistics in Japan Editorial Board. Cancer Statistics in Japan. Tokyo, Japan: Foundation for Promotion of Cancer Research, 2012
- Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. National Medical Care Expenditure, 2010. Tokyo, Japan: Statistics and Information Department, Ministry of Health, Labour and Welfare, 2012
- Kamae I. Perspective of pharmacoeconomic approaches to health technology assessment (1) recent development in assessing innovation. Pharmaceut Med Device Regulatory Sci 2012;43:39-44. Japanese
- Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. J Clin Oncol 2007;25:196-202
- Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin 2008;58:231-44
- Greenberg D, Earle C, Fang CH, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-8
- Kamae MS, Kamae I, Cohen JT, et al. Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. J Med Econ 2011;14:187-93
- Brown T, Pilkington G, Bagust A, et al. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess 2013;17:1–278
- Maher AR, Miake-Lye IM, Beroes JM, et al. Treatment of metastatic non-small cell lung cancer: a systematic review of comparative effectiveness and cost-effectiveness. Washington, DC: Department of Veterans Affairs (US), 2012
- Global Lung Cancer Coalition. Global Awareness of Lung Cancer Symptoms. Available at: http://www.lungcancercoalition.org/ja/pages/facts/types. Accessed Dec 2013
- Sculpher M, Claxton K. Sins of omission and obfuscation: IQWiG’s guidelines on economic evaluation methods. Health Econ 2010;19:1132-6
- Neumann PJ, Cohen JT. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry. [Internet]. Boston, MA: Institute for Clinical Research and Health Policy Studies. Tufts Medical Center. www.cearegistry.org. Accessed October 30, 2012
- Sma4 for Window. Tokyo, Japan: Vector Inc, 2013
- Evans RG. Strained mercy: the economics of Canadian Health Care. Toronto, Ontario, Canada: Butterworths, 1984
- van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E -ratios alongside a clinical trial. Health Econ 1994;3:309-19
- Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11:415-30
- Folland S, Goodman AC, Stano M. Chapter 4: economic effiencey and cost-benefit analysis. The Economics of Health and Health Care. 6th edn. Boston, MA: Prentice Hall, 2010
- Raftery J. NICE and the challenge of cancer drugs. BMJ 2009;338:271-2
- Fukuoka M. Development of target drug and personalized therapy in lung cancer. Med Frontline 2010;65:327-34. Japanese
- Mason AR, Drummond MF. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 2009;45:1188-92
- Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 2008;188:26-8
- Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008;11:771-83
- Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Affairs 2012;31:700-8
- Caplan AL. Will evidence ever be sufficient to resolve the challenge of cost containment? J Clin Oncol 2011;29:1946-8
- Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 2010;70:346-9